A similar beneficial association was seen in an observational study of semaglutide in 83,825 patients with obesity and 598,803 patients with T2DM over 12 months 112 , as well as in 87,676 new users of GLP-1RAs or DPP-4 inhibitors over 4 years 113
That matters for both efficacy and side effects
But doctors are still learning how the drugs might affect, say, a person who is already thin and has alcohol use disorder
By studying the animals in metabolic cages that measure metabolic rate, it was further explored that, despite the GLP-1-MK-801-treated mice being significantly smaller in size and consuming less food than the obese control group, they burned the same amount of calories
We will name the trade-offs
One relates to the reduction in obesity and the risks that go with that